Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The SPI-curcumin-zinc ternary nanocomplex is a food-derived neuroprotective agent composed of soy protein isolate (SPI), curcumin, and zinc. Developed as a potential adjuvant therapy for neurodegenerative disorders, specifically Parkinson's disease, the complex functions by maintaining mitochondrial homeostasis through the activation of mitophagy. Its mechanism of action involves the dual modulation of the PINK1/Parkin and PI3K/AKT/mTOR signaling pathways. Preclinical studies in zebrafish models have demonstrated that the nanocomplex can preserve cerebrovascular integrity, increase cerebral mitochondrial density, and significantly improve locomotor functions such as swimming distance and speed by attenuating oxidative damage and restoring mitochondrial dynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SPI-curcumin-zinc ternary nanocomplex.